IMPROVED GLYCEMIC OUTCOMES WITH THE OMNIPOD® 5 SYSTEM IN PEOPLE WITH TYPE 2 DIABETES USING GLP1-RECEPTOR AGONISTS OR SGLT2 INHIBITORS: SUB-ANALYSIS OF THE SECURE-T2D STUDY
Recommended Citation
Kruger D, Pasquel F, Davis G, Huffman D, Peters A, Parker J, Laffel L, Romeo G, Mathew J, Castorino K, Dungan K, Kipnes M, Jauch E, Oser T, Shah V, Horowitz B, Carlson A, Warren M, Deeb W, Buse J, Reed J, Berner J, Blevins T, Bajaj C, Kanapka L, Raghinaru D, Ly T, Beck R. IMPROVED GLYCEMIC OUTCOMES WITH THE OMNIPOD® 5 SYSTEM IN PEOPLE WITH TYPE 2 DIABETES USING GLP1-RECEPTOR AGONISTS OR SGLT2 INHIBITORS: SUB-ANALYSIS OF THE SECURE-T2D STUDY. Diabetes Technol Ther 2025; 27:e55.
Document Type
Conference Proceeding
Publication Date
3-1-2025
Publication Title
Diabetes Technol Ther
Abstract
Background and Aims: Despite growing use of non-insulin medications including glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose transport protein 2 inhibitors (SGLT2i), many individuals with type 2 diabetes (T2D) are not achieving recommended glycemic targets. The Omnipod® 5 Automated Insulin Delivery (AID) System demonstrated safety and efficacy in adults (≥18y) with T2D and was recently cleared by the US FDA for use in this population (also FDA cleared/CE marked for ages ≥2y with type 1 diabetes). This SECURE-T2D sub-analysis evaluated outcomes in participants using stable doses of GLP1-RA or SGLT2i. Methods: This multicenter single-arm trial enrolled insulintreated adults aged 18-75y with T2D with HbA1c <12.0%. After a 14-day period to capture baseline data, participants initiated 13 weeks of AID. Differences in glycemic outcomes according to GLP1-RA/SGLT2i use were evaluated. Results: A total of 305 participants (mean age 57±11y, 24% Black, 22% Hispanic/Latino, 21% using basal-only) initiated AID. Of these, 55% were using GLP1-RA, 44% were using SGLT2i, and 27% were using both. HbA1c, time in range, and time >250mg/dL (>13.9mmol/L) significantly improved with AID, with similar benefit with or without GLP1-RA/SGLT2i use (Table). No differences were observed for time <70mg/dL (<3.9mmol/L). Total daily insulin was reduced by 16% overall (p<0.001), with similar reductions between users and non-users of GLP1-RA/SGLT2i. Weight increased by 0.8kg in the overall cohort (p<0.001) and did not differ by GLP-1 RA/SGLT2i use. Conclusions: This sub-analysis provides evidence that insulin-treated adults with T2D using the Omnipod 5 System can achieve similar glycemic benefits with minimal hypoglycemia independently of concomitant treatment with GLP1-RA/ SGLT2i therapy. (Table Presented).
Volume
27
First Page
e55
